LEVELSET BIO
Building Pharma-Ready Assets with Disciplined Execution
LevelSet Bio is an integrated drug development company designed to turn high-potential science into de-risked, pharma-ready programs through repeatable, portfolio-scale execution.
Milestone-Driven Capital
De-Risked Development
Pharma-Ready Programs
LevelSet Bio was founded to address one of the biggest failure points in biotech... execution
Too many promising drug programs stall or fail for reasons that have little to do with biology and everything to do with fragmented development, misaligned capital and reactive decision-making.
Our mission is to build a capital-efficient drug development platform that systematically advances high-potential assets with institutional-grade execution. We design programs to withstand regulatory, operational and capital constraints from day one, so strong science is translated into credible, pharma-ready programs.
VISION
What our Approach Enables
Builds a scalable clinical-stage portfolio combining AI insights, disciplined execution and capital efficiency to consistently develop pharma-ready assets.
Portfolio Engine
Centralized portfolio-scale R&D engine
Pharma Alignment
Development design with pharma buyers in mind
Capital Efficiency
Capital-efficient milestone gating
Unified Execution
Integrated CMC, regulatory and clinical execution
Risk Discipline
Structural risk management and early kill criteria
Clean Data Packages
Clean, diligence-ready data packages for partnering
TEAM
Our People Dedicated to Scaling your Assets
Experienced investors and operators across drug development, IP strategy, investing in and scaling companies, asset transactions, supported by global network of advisors.
Leadership Team
Ami Patel Shah, JD
Managing Partner
Read Bio
Marta New, PhD, MBA
Founding Partner
Read Bio
Advisory Board
Alexandre LeBeaut, MD
Scientific Advisor
Read Bio
Matt Tremblay, PhD
Scientific Advisor
Read Bio
Dennis Liotta, PhD
Scientific Advisor
Read Bio
Jeni Fan
Industry Advisor
Read Bio
Partners
LevelSet Bio partners with best-in-class organizations across AI, translational science and global clinical development to build a repeatable, capital-efficient drug development engine.
This ecosystem enables faster decision-making, smarter biomarker strategy and scalable portfolio execution.
